Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares

Posted by Brian Himes on Aug 19th, 2026

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) major shareholder Group Walters acquired 4,335,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the acquisition, the insider directly owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. This trade represents a 32.09% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock traded up $0.14 during mid-day trading on Wednesday, reaching $3.82. 1,694,797 shares of the stock traded hands, compared to its average volume of 1,645,934. The stock has a market capitalization of $273.78 million, a PE ratio of -1.96 and a beta of 1.92. Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.21 and a 12-month high of $6.95. The business’s 50-day moving average is $4.34 and its 200-day moving average is $3.65.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). Equities analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ZNTL has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Mizuho assumed coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They issued an “outperform” rating and a $8.00 price target on the stock. Rodman & Renshaw initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price target on the stock. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $6.75.

Get Our Latest Stock Analysis on ZNTL

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sivia Capital Partners LLC bought a new stake in Zentalis Pharmaceuticals during the 4th quarter worth approximately $27,000. CTC Alternative Strategies Ltd. bought a new position in shares of Zentalis Pharmaceuticals in the first quarter worth approximately $29,000. Qube Research & Technologies Ltd bought a new position in shares of Zentalis Pharmaceuticals in the second quarter worth approximately $37,000. Voleon Capital Management LP purchased a new stake in shares of Zentalis Pharmaceuticals in the third quarter worth $41,000. Finally, State of Wyoming purchased a new stake in shares of Zentalis Pharmaceuticals in the first quarter worth $67,000.

About Zentalis Pharmaceuticals

(Get Free Report)

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.